Tatsuro Yamashita

Mr. Tatsuro Yamashita

orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2023 in Interdisciplinary Neurosurgery
Verified
Journal Article
Open access
TYTomohiro Yamaki
Tomohiro Yamaki
SOShinichi Oka
Shinichi Oka
SISatoshi Iyama
Satoshi Iyama
MSMasanori Sasaki
Masanori Sasaki
RORie Onodera
Rie Onodera
OHOsamu Honmou
Osamu Honmou

11 October 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
RHRyosuke Hirota
Ryosuke Hirota
MSMasanori Sasaki
Masanori Sasaki
SISatoshi Iyama
Satoshi Iyama
KKKota Kurihara
Kota Kurihara
RFRyunosuke Fukushi
Ryunosuke Fukushi
OHOsamu Honmou
Osamu Honmou
Objective: The safety, feasibility, and potential functional improvement following the intravenous infusion of mesenchymal stem cells (MSCs) were investigated in patients with chronic severe spinal cord injury (SCI). Methods: The intravenous infusion of autologous MSCs cultured in auto-serum under Good Manufacturing Practices (GMP) was administered to seven patients with chronic SCI (ranging from 1.3 years to 27 years after the onset of SCI). In addition to evaluating feasibility and safety, neurological function was evaluated using the American Spinal Injury Association Impairment Scale (AIS), International Standards for Neurological Classification of Spinal Cord Injury (ISCSCI-92), and Spinal Cord Independence Measure III (SCIM-III). Results: No serious adverse events occurred. Neither CNS tumors, abnormal cell growth, nor neurological deterioration occurred in any patients. While this initial case series was not blinded, significant functional improvements and increased quality of life (QOL) were observed at 90 and 180 days post-MSC infusion compared to pre-infusion status. One patient who had an AIS grade C improved to grade D within six months after MSC infusion. Conclusions: This case series suggests that the intravenous infusion of autologous MSCs is a safe and feasible therapeutic approach for chronic SCI patients. Furthermore, our data showed significant functional improvements and better QOL after MSC infusion in patients with chronic SCI. A blind large-scale study will be necessary to fully evaluate this possibility.

9 December 2023 in Brain Research
Verified
Journal Article
Closed access
TYTatsuro Yamashita
Tatsuro Yamashita
MSMasanori Sasaki
Masanori Sasaki
YSYuichi Sasaki
Yuichi Sasaki
HNHiroshi Nagahama
Hiroshi Nagahama
SOShinichi Oka
Shinichi Oka
OHOsamu Honmou
Osamu Honmou

2 February 2026 in Spinal Cord
Verified
Journal Article
Closed access
PDF file
RNRyo Nakahara
Ryo Nakahara
YTYousuke Tanaka
Yousuke Tanaka
KKKotaro Kojima
Kotaro Kojima
HMHajime Miyashita
Hajime Miyashita
HSHiroki Sato
Hiroki Sato
SSSoshi Samejima
Soshi Samejima